Ascites Epidemiology

Ascites Insights and Trends

• According to DelveInsight’s estimates, in 2025, Ascites cases were distributed across the 7MM, with the highest share observed in the United States, followed by the EU4 & UK, while Japan accounted for a comparatively smaller proportion of cases.
• Ascites is more prevalent in countries due to the high burden of chronic liver diseases, particularly cirrhosis caused by alcohol-related liver disease, viral hepatitis, and metabolic dysfunction-associated steatotic liver disease (MASLD). 
• Males face a higher lifetime risk of developing ASCITES and experience a greater disease burden compared to females. This disparity is largely attributed to the higher prevalence of chronic liver diseases, alcohol-related liver injury, viral hepatitis, and other underlying risk factors among men, contributing to increased progression to decompensated cirrhosis and fluid accumulation.
• The growing global burden of chronic liver diseases, rising prevalence of cirrhosis, and increasing rates of liver decompensation are expected to sustain the Ascites market over the next decade. Improving early diagnosis and disease management, expanding access to advanced therapies, and the development of effective targeted treatments will remain key drivers of future market growth.

Ascites Epidemiology Forecast in the 7MM

• 2025 Prevalent Cases of Ascites: ~XXXX million
• Ascites Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Ascites– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Ascites, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Ascites Understanding and Diagnosis Algorithm

Ascites Overview

Ascites is a clinical condition characterized by the abnormal accumulation of fluid within the peritoneal cavity, most commonly resulting from underlying liver disease such as cirrhosis, portal hypertension, malignancies, heart failure, or infections. The condition develops due to imbalances in hydrostatic and oncotic pressures, along with sodium and water retention, leading to progressive fluid buildup in the abdomen. Ascites is most frequently associated with advanced chronic liver disease but can occur across a wide range of underlying systemic and intra-abdominal disorders. It primarily affects individuals with chronic hepatic conditions, alcohol-related liver injury, viral hepatitis, or malignancy, with severity influenced by the progression of the underlying disease and associated complications.

Ascites Diagnosis

Ascites is diagnosed through clinical examination supported by imaging and Ascitic fluid analysis. Key investigations include abdominal ultrasound and diagnostic paracentesis with fluid studies (SAAG, protein, cell count, and culture), along with liver and renal function tests to identify the underlying cause and guide management.

Note: Further details are provided in the report.

Ascites Epidemiology

Key Findings from Ascites Epidemiological Analysis and Forecast 

• The total prevalent cases of Ascites due to cirrhosis across the 7MM is expected to increase throughout the study period (2022–2036), driven by the growing burden of chronic liver diseases, increasing rates of alcohol-related liver injury, MASLD, viral hepatitis, and improved survival of patients with advanced cirrhosis. 
• Among the 7MM, the United States has the highest prevalent cases of Ascites due to cirrhosis of Ascites in 2025.
• Among the EU-4 & UK, Germany reported the highest prevalent cases of Ascites due to cirrhosis, followed by UK and France. Spain was found to have the least cases in 2025 among all European countries. 
• In 2025, Malignant Ascites cases are calculated from ovarian cancer, stomach cancer, breast cancer, and colorectal cancer. Breast cancer accounted for the highest number of prevalent cases of Ascites from these cancers in the United States.
• The observed male predominance and earlier onset of Ascites highlight the importance of timely identification and management of underlying liver disease, targeted risk-reduction strategies, and early intervention to prevent disease progression and associated complications.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Ascites, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Ascites Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Ascites? What will be the growth opportunities across the 7MM concerning the patient population with Ascites?
• What is the historical and forecasted Ascites patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.